Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsImproving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches
Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer
Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer
Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer
Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer
Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly
Navigating Advances in Cystic Fibrosis Care
1.
No Solace From Drug Scarcities; Novel Guidelines Regarding Lymphedema; A "Good" Patient Is Forgotten.
2.
New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.
3.
Providing essential cancer care to rural communities
4.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
4.
PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision
5.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge